FRANKFURT (Reuters) - Bayer struck a collaboration deal with Roche’s Foundation Medicine Inc. to develop test kits for genetic sequencing of tumor cells to identify cancer patients that benefit from Bayer’s Vitrakvi drug. Vitrakvi, which Bayer acquired from Eli Lilly’s Loxo Oncology, has been shown to shrink tumors in about 1 percent of patients across a range 24 different cancer types. Identifying those patients requires advanced genetic diagnostic tools. Reporting by Ludwig Burger; Editing by Thomas Seythal
Bayer has agreed a deal with cancer research to develop test kits which can be used to identify patients for its breast cancer therapy . The kits will enable the genetic sequencing of tumour ##s to find individuals who will benefit from the drug , which research shows is capable of shrinking tumours from 24 different types of tumors in around 90 % of patients .